FDA
-
-
-
-
-
-
-
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
-
-
-
-
-
-
-
ContraFect (CFRX) Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections
-
-
-
-
-
-
-
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis
-
-
-
-
-
-
-
ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibi
-
-
-
-
-
-
-
Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases
-
-
-
-
-
-
-
ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference
-
-
-
-
-
-
-
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections
-
251,639 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All